{"id":"docetaxel-monotherapy","safety":{"commonSideEffects":[{"effect":"Nausea","drugRate":"37.2%","placeboRate":"","totalAtRisk":1361,"totalAffected":506,"trialsReporting":7},{"effect":"Diarrhoea","drugRate":"31.3%","placeboRate":"","totalAtRisk":1361,"totalAffected":426,"trialsReporting":7},{"effect":"Decreased appetite","drugRate":"30.9%","placeboRate":"","totalAtRisk":1361,"totalAffected":420,"trialsReporting":7},{"effect":"Anaemia","drugRate":"30.1%","placeboRate":"","totalAtRisk":1361,"totalAffected":410,"trialsReporting":7},{"effect":"Fatigue","drugRate":"27.8%","placeboRate":"","totalAtRisk":1361,"totalAffected":378,"trialsReporting":7},{"effect":"Asthenia","drugRate":"23.3%","placeboRate":"","totalAtRisk":1245,"totalAffected":290,"trialsReporting":6},{"effect":"Constipation","drugRate":"21.0%","placeboRate":"","totalAtRisk":1361,"totalAffected":286,"trialsReporting":7},{"effect":"Vomiting","drugRate":"18.5%","placeboRate":"","totalAtRisk":1361,"totalAffected":252,"trialsReporting":7},{"effect":"Weight decreased","drugRate":"17.1%","placeboRate":"","totalAtRisk":1361,"totalAffected":233,"trialsReporting":7},{"effect":"Neutrophil count decreased","drugRate":"14.9%","placeboRate":"","totalAtRisk":1361,"totalAffected":203,"trialsReporting":7},{"effect":"Stomatitis","drugRate":"13.9%","placeboRate":"","totalAtRisk":1361,"totalAffected":189,"trialsReporting":7},{"effect":"Hypertension","drugRate":"13.8%","placeboRate":"","totalAtRisk":1361,"totalAffected":188,"trialsReporting":7},{"effect":"Hypothyroidism","drugRate":"15.9%","placeboRate":"","totalAtRisk":1091,"totalAffected":174,"trialsReporting":6},{"effect":"Arthralgia","drugRate":"12.3%","placeboRate":"","totalAtRisk":1361,"totalAffected":168,"trialsReporting":7},{"effect":"Pruritus","drugRate":"11.9%","placeboRate":"","totalAtRisk":1361,"totalAffected":162,"trialsReporting":7},{"effect":"Dyspnoea","drugRate":"11.2%","placeboRate":"","totalAtRisk":1361,"totalAffected":153,"trialsReporting":7},{"effect":"Rash","drugRate":"11.2%","placeboRate":"","totalAtRisk":1361,"totalAffected":153,"trialsReporting":7},{"effect":"Cough","drugRate":"10.9%","placeboRate":"","totalAtRisk":1361,"totalAffected":149,"trialsReporting":7},{"effect":"Aspartate aminotransferase increased","drugRate":"11.0%","placeboRate":"","totalAtRisk":1276,"totalAffected":140,"trialsReporting":6},{"effect":"Blood creatinine increased","drugRate":"11.6%","placeboRate":"","totalAtRisk":1194,"totalAffected":139,"trialsReporting":6},{"effect":"Pyrexia","drugRate":"10.1%","placeboRate":"","totalAtRisk":1361,"totalAffected":137,"trialsReporting":7},{"effect":"Alanine aminotransferase increased","drugRate":"10.7%","placeboRate":"","totalAtRisk":1276,"totalAffected":137,"trialsReporting":6},{"effect":"Headache","drugRate":"9.8%","placeboRate":"","totalAtRisk":1361,"totalAffected":133,"trialsReporting":7},{"effect":"Neutropenia","drugRate":"15.5%","placeboRate":"","totalAtRisk":850,"totalAffected":132,"trialsReporting":3},{"effect":"Oedema peripheral","drugRate":"9.7%","placeboRate":"","totalAtRisk":1361,"totalAffected":132,"trialsReporting":7},{"effect":"Back pain","drugRate":"10.1%","placeboRate":"","totalAtRisk":1276,"totalAffected":129,"trialsReporting":6},{"effect":"Abdominal pain","drugRate":"9.2%","placeboRate":"","totalAtRisk":1361,"totalAffected":125,"trialsReporting":7},{"effect":"Dysgeusia","drugRate":"11.2%","placeboRate":"","totalAtRisk":1102,"totalAffected":123,"trialsReporting":5},{"effect":"Dizziness","drugRate":"9.6%","placeboRate":"","totalAtRisk":1276,"totalAffected":122,"trialsReporting":6},{"effect":"Platelet count decreased","drugRate":"8.5%","placeboRate":"","totalAtRisk":1276,"totalAffected":109,"trialsReporting":6},{"effect":"Palmar-plantar erythrodysaesthesia syndrome","drugRate":"9.5%","placeboRate":"","totalAtRisk":1091,"totalAffected":104,"trialsReporting":6},{"effect":"Insomnia","drugRate":"8.5%","placeboRate":"","totalAtRisk":1180,"totalAffected":100,"trialsReporting":6},{"effect":"Hypokalaemia","drugRate":"7.1%","placeboRate":"","totalAtRisk":1361,"totalAffected":97,"trialsReporting":7},{"effect":"Alopecia","drugRate":"6.9%","placeboRate":"","totalAtRisk":1361,"totalAffected":94,"trialsReporting":7},{"effect":"White blood cell count decreased","drugRate":"9.2%","placeboRate":"","totalAtRisk":966,"totalAffected":89,"trialsReporting":4},{"effect":"Myalgia","drugRate":"6.1%","placeboRate":"","totalAtRisk":1361,"totalAffected":83,"trialsReporting":7},{"effect":"Pain in extremity","drugRate":"5.7%","placeboRate":"","totalAtRisk":1361,"totalAffected":77,"trialsReporting":7},{"effect":"Dyspepsia","drugRate":"7.5%","placeboRate":"","totalAtRisk":993,"totalAffected":74,"trialsReporting":4},{"effect":"Dry skin","drugRate":"5.3%","placeboRate":"","totalAtRisk":1361,"totalAffected":72,"trialsReporting":7},{"effect":"Proteinuria","drugRate":"12.8%","placeboRate":"","totalAtRisk":491,"totalAffected":63,"trialsReporting":3},{"effect":"Neuropathy peripheral","drugRate":"4.8%","placeboRate":"","totalAtRisk":1218,"totalAffected":58,"trialsReporting":6},{"effect":"Abdominal pain upper","drugRate":"4.7%","placeboRate":"","totalAtRisk":1160,"totalAffected":55,"trialsReporting":5},{"effect":"Blood alkaline phosphatase increased","drugRate":"4.9%","placeboRate":"","totalAtRisk":1109,"totalAffected":54,"trialsReporting":5},{"effect":"Malaise","drugRate":"7.6%","placeboRate":"","totalAtRisk":682,"totalAffected":52,"trialsReporting":3},{"effect":"Urinary tract infection","drugRate":"5.0%","placeboRate":"","totalAtRisk":993,"totalAffected":50,"trialsReporting":4},{"effect":"Hypoalbuminaemia","drugRate":"5.6%","placeboRate":"","totalAtRisk":890,"totalAffected":50,"trialsReporting":4},{"effect":"Thrombocytopenia","drugRate":"5.3%","placeboRate":"","totalAtRisk":836,"totalAffected":44,"trialsReporting":3},{"effect":"Mucosal inflammation","drugRate":"4.8%","placeboRate":"","totalAtRisk":910,"totalAffected":44,"trialsReporting":5},{"effect":"Hypomagnesaemia","drugRate":"4.3%","placeboRate":"","totalAtRisk":975,"totalAffected":42,"trialsReporting":5},{"effect":"Hypophosphataemia","drugRate":"4.2%","placeboRate":"","totalAtRisk":979,"totalAffected":41,"trialsReporting":4}]},"_chembl":{"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"allNames":"docetaxel monotherapy","_dailymed":null,"mechanism":{"target":"TUBB","drugClass":"Microtubule-stabilizing agent","explanation":"Docetaxel works by binding to a protein called tubulin, which is essential for cell division. By stabilizing the structures made from tubulin (microtubules), docetaxel prevents cancer cells from dividing and causes them to die.","oneSentence":"Docetaxel binds to tubulin, stabilizing microtubules and preventing their depolymerization, leading to cell cycle arrest and apoptosis in cancer cells."},"_scrapedAt":"2026-03-28T00:43:53.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2025,"annualRevenue":798,"revenueSource":"SEC 8-K Bristol-Myers Squibb (2026-02-05)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:02.606798","revenueExtractedBy":"revenue-sec"},"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:37:27.121847+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06863272","phase":"PHASE1, PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":"Castration-Resistant Prostatic Cancer, Metastasis","enrollment":360},{"nctId":"NCT06745908","phase":"PHASE3","title":"ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-01","conditions":"NSCLC Stage IV","enrollment":460},{"nctId":"NCT07487896","phase":"PHASE3","title":"A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-04-30","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":440},{"nctId":"NCT07291037","phase":"PHASE3","title":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-31","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":400},{"nctId":"NCT06952504","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-22","conditions":"Endometrial Cancer","enrollment":1123},{"nctId":"NCT06012435","phase":"PHASE3","title":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2024-02-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":703},{"nctId":"NCT06496178","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Merus B.V.","startDate":"2024-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":500},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":"Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer","enrollment":270},{"nctId":"NCT07144280","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-29","conditions":"Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma","enrollment":680},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT07459751","phase":"PHASE2, PHASE3","title":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-09","conditions":"Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","enrollment":671},{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":572},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06120075","phase":"PHASE1","title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2024-01-19","conditions":"Advanced Cancer","enrollment":91},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT04895709","phase":"PHASE1, PHASE2","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-05-27","conditions":"Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer","enrollment":949},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT05381909","phase":"PHASE1","title":"A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2022-07-06","conditions":"Solid Tumor, Adult","enrollment":157},{"nctId":"NCT07417735","phase":"PHASE3","title":"SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-03-18","conditions":"Locally Advanced/Metastatic/Recurrent ESCC","enrollment":436},{"nctId":"NCT06724159","phase":"","title":"Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2024-12-13","conditions":"Genitourinary Cancers","enrollment":500},{"nctId":"NCT05631262","phase":"PHASE2","title":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","startDate":"2022-11-30","conditions":"Selected Subjects With Advanced Solid Tumors","enrollment":321},{"nctId":"NCT03917381","phase":"PHASE1, PHASE2","title":"GEN1046 Safety Trial in Patients With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2019-05-14","conditions":"Solid Tumors","enrollment":429},{"nctId":"NCT04884282","phase":"PHASE2","title":"Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2021-10-12","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":105},{"nctId":"NCT05094336","phase":"PHASE1, PHASE2","title":"A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-02-01","conditions":"Advanced MTAP-null Solid Tumors","enrollment":329},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT06266299","phase":"PHASE1","title":"A Study of KK2269 in Adult Participants With Solid Tumors","status":"RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-18","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma","enrollment":101},{"nctId":"NCT05867420","phase":"PHASE1, PHASE2","title":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","status":"RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2023-08-02","conditions":"Advanced Solid Tumors","enrollment":594},{"nctId":"NCT07330050","phase":"PHASE2","title":"WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":31},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT05006794","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-09-15","conditions":"Solid Malignancies","enrollment":145},{"nctId":"NCT04471428","phase":"PHASE3","title":"Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":366},{"nctId":"NCT06724042","phase":"PHASE1","title":"Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"InSilico Medicine Hong Kong Limited","startDate":"2026-06-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors","enrollment":159},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT05450692","phase":"PHASE3","title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-15","conditions":"Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":594},{"nctId":"NCT07230626","phase":"PHASE3","title":"SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-11-20","conditions":"Cervical Cancer","enrollment":412},{"nctId":"NCT04794699","phase":"PHASE1","title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2021-04-14","conditions":"Solid Tumor","enrollment":180},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT02817633","phase":"PHASE1","title":"A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2016-07-08","conditions":"Neoplasms","enrollment":463},{"nctId":"NCT06228326","phase":"PHASE1, PHASE2","title":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","startDate":"2024-04-17","conditions":"Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult","enrollment":250},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT05639751","phase":"PHASE1","title":"PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation","status":"COMPLETED","sponsor":"Prelude Therapeutics","startDate":"2023-05-02","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers","enrollment":135},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT06874114","phase":"","title":"An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-02-28","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":700},{"nctId":"NCT05076760","phase":"PHASE1","title":"MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Memgen, Inc.","startDate":"2022-04-21","conditions":"Solid Tumor, Advanced Cancer, Metastatic Cancer","enrollment":40},{"nctId":"NCT04725188","phase":"PHASE2","title":"Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-20","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":255},{"nctId":"NCT03976375","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-26","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":422},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT02975934","phase":"PHASE3","title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-06-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":405},{"nctId":"NCT03421288","phase":"PHASE2","title":"Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-09-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":677},{"nctId":"NCT05005728","phase":"PHASE2","title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Xencor, Inc.","startDate":"2021-10-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":72},{"nctId":"NCT04721015","phase":"PHASE1","title":"Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-23","conditions":"Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)","enrollment":81},{"nctId":"NCT03884556","phase":"PHASE1","title":"TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2019-04-10","conditions":"Solid Tumor, Lymphoma","enrollment":56},{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":79},{"nctId":"NCT07007988","phase":"PHASE1","title":"A Phase I Study of SIM0388 in Participants With Malignant Ascites.","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2025-04-24","conditions":"Malignant Ascites","enrollment":50},{"nctId":"NCT04140526","phase":"PHASE1, PHASE2","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoC4, Inc.","startDate":"2020-09-16","conditions":"Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma","enrollment":733},{"nctId":"NCT05267470","phase":"PHASE1","title":"A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)","status":"TERMINATED","sponsor":"Amgen","startDate":"2022-03-29","conditions":"Squamous-Cell Non-Small-Cell Lung Cancer","enrollment":74},{"nctId":"NCT06892431","phase":"PHASE2","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy","enrollment":150},{"nctId":"NCT04256707","phase":"PHASE1, PHASE2","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-01-14","conditions":"Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors","enrollment":126},{"nctId":"NCT04880863","phase":"PHASE2","title":"NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC","status":"COMPLETED","sponsor":"NeoTX Therapeutics Ltd.","startDate":"2021-10-26","conditions":"Non-small Cell Lung Cancer","enrollment":38},{"nctId":"NCT01957735","phase":"PHASE1","title":"BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors","status":"COMPLETED","sponsor":"BPGbio","startDate":"2013-10","conditions":"Metastatic Cancer, Cancer, Solid Tumor","enrollment":97},{"nctId":"NCT06629597","phase":"PHASE3","title":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-12-31","conditions":"Nasopharyngeal Carcinoma","enrollment":400},{"nctId":"NCT02802423","phase":"PHASE1, PHASE2","title":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"BioLite, Inc.","startDate":"2026-01-01","conditions":"Triple Negative Breast Cancer","enrollment":44},{"nctId":"NCT05431270","phase":"PHASE1, PHASE2","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2022-08-11","conditions":"Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55},{"nctId":"NCT06016062","phase":"PHASE1, PHASE2","title":"A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-09-14","conditions":"Solid Tumor","enrollment":221},{"nctId":"NCT06775483","phase":"PHASE2","title":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-01-17","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT03854227","phase":"PHASE1","title":"A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-03-14","conditions":"Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":54},{"nctId":"NCT06735326","phase":"PHASE2","title":"Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-11-27","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":105},{"nctId":"NCT04745988","phase":"PHASE2","title":"An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2021-11-11","conditions":"Gastric Cancer","enrollment":43},{"nctId":"NCT05713838","phase":"PHASE2","title":"Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-08-28","conditions":"Esophagus Adenocarcinoma","enrollment":32},{"nctId":"NCT02358473","phase":"PHASE1","title":"Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2015-01","conditions":"Non-Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT06525350","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-07","conditions":"Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression","enrollment":256},{"nctId":"NCT06469060","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":34},{"nctId":"NCT06467500","phase":"PHASE2","title":"A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy","status":"RECRUITING","sponsor":"Xin-Hua Xu","startDate":"2024-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT03095612","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-03-22","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT04062656","phase":"PHASE2","title":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2019-09-26","conditions":"Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction","enrollment":21},{"nctId":"NCT03837353","phase":"PHASE1, PHASE2","title":"A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2019-04-01","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT05673590","phase":"PHASE3","title":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2023-05-12","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":612},{"nctId":"NCT05094804","phase":"PHASE1, PHASE2","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","status":"UNKNOWN","sponsor":"OncoResponse, Inc.","startDate":"2021-09-09","conditions":"Cancer, Tumor, Solid, Malignant Neoplasm","enrollment":172},{"nctId":"NCT03742193","phase":"PHASE2","title":"Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-08-11","conditions":"Osteosarcoma, Pulmonary Metastases, Apatinib","enrollment":43},{"nctId":"NCT04165993","phase":"PHASE2","title":"Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2019-12-31","conditions":"Metastatic Breast Cancer","enrollment":68},{"nctId":"NCT02611960","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-18","conditions":"Nasopharyngeal Neoplasms","enrollment":233},{"nctId":"NCT05116891","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cantargia AB","startDate":"2021-09-22","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04146064","phase":"","title":"Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-02-24","conditions":"NSCLC, Melanoma, Kidney Cancer","enrollment":425},{"nctId":"NCT02154490","phase":"","title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-07-08","conditions":"Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":1864},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT03386721","phase":"PHASE2","title":"Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-02-19","conditions":"Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers","enrollment":256},{"nctId":"NCT05327231","phase":"PHASE1","title":"IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2020-07-09","conditions":"Gastric Cancer","enrollment":33},{"nctId":"NCT02071862","phase":"PHASE1","title":"Study of the Glutaminase Inhibitor CB-839 in Solid Tumors","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2014-02","conditions":"Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer","enrollment":210},{"nctId":"NCT03787251","phase":"PHASE2","title":"A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib","status":"WITHDRAWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2019-01-01","conditions":"Esophageal Neoplasms","enrollment":""},{"nctId":"NCT05173142","phase":"PHASE1, PHASE2","title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Hutchison Medipharma Limited","startDate":"2022-01-22","conditions":"Solid Tumor","enrollment":141},{"nctId":"NCT04144582","phase":"PHASE2","title":"Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Yongchang Zhang","startDate":"2019-01-01","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04165031","phase":"PHASE1, PHASE2","title":"A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2019-11-28","conditions":"Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":5},{"nctId":"NCT04654403","phase":"NA","title":"Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-01-01","conditions":"Esophageal Cancer","enrollment":337}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":146,"_revenueScrapedAt":"2026-04-01 10:47:02.629581+00","rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Docetaxel monotherapy","genericName":"docetaxel-monotherapy","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":6,"trialStats":{"total":14,"withResults":8},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:37:27.121847+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}